Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

计划入组 23,670 人 · 首次发布于 2021 年 5 月 27 日

Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults

首次发布于 2024 年 8 月 22 日

Monovalent Recombinant COVID19 Vaccine

计划入组 40 人 · 首次发布于 2020 年 7 月 1 日

monovalent vaccine

Diphtheria/Tetanus Toxoid combined vaccine (Seqirus)

H7N9 monovalent vaccine

Bioaster

Belgium

BIOSTEM TECHNOLOGIES

华仁药业股份有限公司

COVID-19 Boosters Reduce Hospitalization Risk by 29% in Cancer Patients, Large Multi-Center Study Shows

FDA Authorizes Second Omicron Booster for High-Risk Groups, Simplifies COVID-19 Vaccine Strategy

Pfizer's Comirnaty Vaccine Transitions to Endemic Phase with Sustained European Market Presence